Cosmos Health Inc.
0.9262-0.01 (-1.43%)
Oct 29, 4:00:01 PM EDT · NasdaqCM · COSM · USD
Key Stats
Market Cap
28.73MP/E (TTM)
-Basic EPS (TTM)
-1.04Dividend Yield
0%Recent Filings
8-K
Regains Nasdaq bid price compliance
Cosmos Health Inc. regained Nasdaq compliance on October 15, 2025, after its common stock closed at or above $1.00 per share for 18 consecutive business days from September 22 to October 15, resolving a deficiency flagged in November 2024. CEO Greg Siokas credited organic progress from strategic initiatives and solid fundamentals. Compliance secured. The company eyes ongoing value creation amid risks like financing needs and geopolitical tensions.
8-K
New board director appointed
Cosmos Health Inc. appointed Theodoros C. Karkantzos to its Board of Directors on September 30, 2025, following election at the annual stockholder meeting, with his term expiring in 2026. He also joined the Nominating and Corporate Governance Committee, bringing over 15 years in investment, business development, and expertise in finance, strategy, and real estate from roles like co-founding Blue Dot Digital Agency. Compensation includes a $10,000 annual Board fee, $5,000 committee fee, and equity grants under the 2025 Omnibus Incentive Plan. This bolsters governance with his Cambridge MPhil credentials. No prior arrangements tied to the appointment.
8-K
CEO letter unveils growth strategy
Cosmos Health released its CEO's annual letter on September 29, 2025, highlighting 2024 revenue of $54.43 million, up 2%, with operating expenses down 24% yet adjusted EBITDA at ($3.73 million) due to R&D investments. Key milestones include a $300 million digital asset financing facility for treasury reserves and growth, U.S. manufacturing expansion via NOOR Collagen targeting over $12 million in revenue at 75% margins, and global Sky Premium Life rollout into the U.S. and Middle East. Momentum builds in 2025 with H1 revenue up 11.7% to $28.46 million and gross profit surging 53%; guidance eyes $155.8 million revenue and $29.4 million adjusted EBITDA by 2027. This digital pivot diversifies risks but exposes to crypto volatility.
10-Q
Q2 FY2025 results
Cosmos Health posted Q2 revenue of $14.7M, up 11.7% y/y from $13.2M, with gross profit surging 51.7% to $1.2M on a richer mix of nutraceuticals and contract manufacturing. Yet operating loss widened to $2.6M from $2.5M, driven by higher salaries for new hires at manufacturing unit Cana SA, while net loss hit $2.8M versus $2.6M last year, widened by $0.2M non-cash interest and fair-value changes on fresh convertible notes. Cash climbed to $0.7M from $0.3M at year-start, fueled by $2.2M financing inflows including new debt facilities, though free cash flow stayed negative at $1.4M used in operations minus minimal capex. Debt totaled $14.8M with lines of credit at $8.2M, but an August $8M senior secured note closing bolsters liquidity for digital assets and working capital. Revenue skewed heavily to Greece at 96.6%. Competition from generics and biosimilars pressures margins.
8-K
Closes $8M convertible note
Cosmos Health Inc. closed its initial issuance of an $8,000,000 9% OID senior secured convertible promissory note to an institutional investor on August 7, 2025, under a previously announced securities purchase agreement. The note matures August 7, 2027, with interest payable monthly in cash or shares, convertible into common stock at $1.05 or market price, subject to a 4.99% beneficial ownership cap. This senior debt bolsters liquidity while capping dilution. Default hikes rates to 16%.
IPO
Employees
Sector
Industry
AIXN
AIXIN LIFE INTERNATIONAL INC
0.18+0.00
CAH
Cardinal Health, Inc.
164.47+1.68
COR
Cencora, Inc.
333.17-2.47
CRLBF
Cresco Labs Inc.
1.20-0.00
CSCIF
COSCIENS Biopharma Inc
2.57+0.00
EBOSF
EBOS GROUP
23.75+0.00
OGN
Organon & Co.
6.34-0.32
SNYR
Synergy CHC Corp.
2.26-0.14
UPC
Universe Pharmaceuticals Inc
4.82-0.29
VTRS
Viatris Inc.
10.27-0.02